Thomas Bernard Freeman

Title: Innovations of Thomas Bernard Freeman

Introduction

Thomas Bernard Freeman is an accomplished inventor based in San Bruno, CA (US). He has made significant contributions to the field of pharmaceuticals, particularly in developing methods to counteract the cardiotoxic effects of chemotherapy. With a total of 4 patents to his name, Freeman's work is vital in improving cancer treatment outcomes.

Latest Patents

Freeman's latest patents focus on pharmaceutical compositions and methods for countering chemotherapy-induced cardiotoxicity. These disclosures provide innovative methods and compositions aimed at reducing or eliminating cardiotoxicity, especially that induced by cancer treatments. The methods often involve administering protective agents such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, and others in conjunction with cancer drugs. The compositions may also include co-formulations of protective agents with different protective agents or with cancer treatments, such as anthracycline drugs.

Career Highlights

Throughout his career, Freeman has worked with notable companies, including Auransa Inc. and Sct II LLC. His expertise in pharmaceutical innovations has positioned him as a key player in the industry, contributing to advancements that enhance patient care.

Collaborations

Freeman has collaborated with esteemed colleagues, including Christopher G. Armstrong and Kevin J. Kim. These partnerships have fostered a collaborative environment that encourages innovation and the development of groundbreaking solutions in the pharmaceutical field.

Conclusion

Thomas Bernard Freeman's contributions to the pharmaceutical industry are noteworthy, particularly in addressing the challenges posed by chemotherapy-induced cardiotoxicity. His innovative approaches and collaborations continue to pave the way for advancements in cancer treatment.